Skip to main content

Table 1 Cross-sectional studies in populations including Down syndrome and familial Alzheimer's disease due to trisomy 21 or autosomal dominant mutations, respectively

From: Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker

      Values in DS patients compared to controls   Values in dDS compared to cnDS
Study Subjects Mean age (years) Platform and antibodies %CV 1-40 1-42 1-42/Aβ1-40  1-40 1-42 1-42/Aβ1-40
Schupf et al. 2001 [52] 97 cnDS 51.9 ELISA - -   = -
  11 dDS 56 6E10         
    R182         
    R165         
Schupf et al. 2007 [32]    ELISA - - - -   = -
    6E10         
    R182         
    R165         
Matsuoka et al. 2009 [53] 148 cnDS 54.2 ELISA <11.0% - - -   = =
  52 dDS 56.0 82E1         
    1A10         
    1C3         
Prasher et al. 2010 [35] 83 cnDS 49.0 ELISA - - - - =   = =   a
  52dDS 56.8 6E10         
    R182         
    R165         
Head et al. 2011 [34] 11 yCN 46.5 ELISA - =   - - -
  12 aCN 74.2 Wako         
  17 AD 75.3          
  43 cnDS 45          
  52 dDS 53.3          
Coppus et al. 2012 [54] 62 dDS 54 xMAP - - - -   = =
  264 cnDS 50.6 INNO-BIA         
Reiman et al. 2012 [51] 10 PSEN1+ CN 23 xMAP - - - -   - - -
  10 PSEN1- CN 24 INNO-BIA         
  1. adDS who had a dementia history of 4 or more years had increased Aβ1-42/Aβ1-40 compared with dDS with a more recent diagnosis. aCN, aged cognitively normal controls; AD, Alzheimer's disease; CN, cognitively normal; cnDS, cognitively normal Down syndrome; CV, coefficient of variation; dDS, demented Down syndrome; DS, Down syndrome; yCN, young cognitively normal controls.